Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer

  • Merck & Co Inc MRK and Eisai Co Ltd ESALY presented final analysis results from Phase 3 LEAP-002 of Keytruda plus Lenvima versus Lenvima as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). 
  • In the final analysis of the trial, there was a trend toward improvement for one of the study's dual primary endpoints, overall survival (OS); however, the results did not meet statistical significance.
  • Related: Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal.
  • The median OS was 21.2 months for Keytruda plus Lenvima and 19.0 months for Lenvima monotherapy. 
  • Additionally, Keytruda plus Lenvima resulted in a trend toward improvement in progression-free survival (PFS) versus Lenvima monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance.
  • Price Action: MRK shares closed lower by 0.09% at $87.34 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!